Tag Archives: Gilead

Large-Scale Injectable PrEP Trial Begins

News-Medical reports: The first large-scale clinical trial of a long-acting injectable drug for HIV prevention began today. The study, sponsored by the National Institutes of Health, will examine whether a long-acting form of the investigational anti-HIV drug cabotegravir injected once every 8 weeks can safely protect men and transgender women from HIV infection at least as well as the anti-HIV ...

Read More »

ATLANTA: County Launches No-Cost PrEP Clinic

Fulton County, Georgia – whose county seat is Atlanta – has launched a no-cost PrEP clinic in collaboration with Gilead, the maker of Truvada. Matt Hennie reports at Project Q Atlanta: Fulton County health officials openly embraced PrEP for HIV prevention on Friday, launching a new clinic for the once-a-day pill to combat the virus among high-risk groups, including gay ...

Read More »

AHF Files FDA Complaint Against Gilead For Promoting “Off-Label” PrEP Usage Of Truvada [VIDEO]

Via press release from the ever-combative AHF: Advocates from AIDS Healthcare Foundation (AHF) stepped up efforts to ensure that Gilead Sciences, Inc. be held accountable for promoting off-label use of Truvada for use as pre-exposure prophylaxis (PrEP) to prevent HIV infection. AHF also wants Gilead to be compelled to promote and market use of its AIDS treatment in accordance with ...

Read More »

Legendary AIDS Activists: End PrEP Profiteering

Last night a group of noted AIDS activists including Peter Staley and Larry Kramer met in the very apartment where the Gay Men’s Health Crisis was formed 33 years ago to denounce the “abusive pricing” and “profiteering” which continues to put cost of PrEP beyond the means of much of the world. The group has issued a statement: We – ...

Read More »

AHF Launches Anti-PrEP Ad Campaign

The combative and controversial AIDS Healthcare Foundation is launching a print ad campaign against the use of Truvada as a daily HIV preventive. Via press release: AHF’s ‘PrEP Facts’ ad campaign educating the public about adherence issues and PrEP initially started running this week in a few newspapers, magazines and online outlets in California and will continue and expand to ...

Read More »

NEW YORK: State Endorses Truvada For Daily Use As HIV Preventive

The New York state Department of Health has officially endorsed daily use of the Gilead medication Truvada for the prevention of HIV infection. After months of anticipation, the Health Department’s AIDS Institute released thorough clinical guidelines for pre-exposure prophylaxis, commonly known as PrEP, which is a daily dose of HIV medication that people who are HIV-negative but at-risk of contracting ...

Read More »

FDA Approves 4-In-1 HIV Med

The FDA has approved Gilead’s latest combination once-a-day HIV pill which has been known as “the Quad.” Via FDA press release: Stribild contains two previously approved HIV drugs plus two new drugs, elvitegravir and cobicistat. Elvitegravir is an HIV integrase strand transfer inhibitor, a drug that interferes with one of the enzymes that HIV needs to multiply. Cobicistat, a pharmacokinetic ...

Read More »

Four-In-One HIV Med News

Gilead has announced the results of Stage 3 clinical trials of “the Quad,” which would be the world’s first four-in-one daily HIV pill. The Quad contains two new (and not yet FDA approved) drugs: the integrase inhibitor, Elvitegravir, and Cobicistat, which is meant to mitigate the side-effects of Elvitegravir. Via press release: “These data show that the Quad is as ...

Read More »

FDA Approves New HIV Med

Yesterday the FDA approved the second all-in-one daily combination pill for the treatment of HIV infection. The first such medication, Atripla, has been on the market for several years. Complera, a complete single-tablet regimen containing Janssen Therapeutics’ Edurant (rilpivirine) and Gilead Sciences’ Viread (tenofovir) and Emtriva (emtricitabine), was approved August 10 by the U.S. Food and Drug Administration (FDA), according ...

Read More »

Good News/Bad News For Gilead

It’s a complicated turn of events for Gilead, the maker of HIV drug Viread. The 9th Circuit Court has reinstated a securities class action suit against the drug maker which claims that Gilead had misled investors about the demand for Viread. The suit charges that Gilead fostered demand for Viread by using improper marketing such as “aggressively promoting off-label uses.” ...

Read More »